Home Tags Immunogen

Tag: Immunogen

ImmunoGen to Prioritize Continued Development of Mirvetuximab Soravtansine

Waltham, Massachusetts, based ImmunoGen, expanding field of antibody-drug conjugates (ADCs) with the development of the next generation of targeted anti-cancer agents, has completed an...

ImmunoGen and FDA Discuss Ongoing Development for Mirvetuximab Soravtansine

The United States Food and Drug Administration (FDA) has recommended that ImmunoGen conducts a new Phase III randomized trial to evaluate the safety and...
San Diego Skyline from Coronado Island

Speaker’s Perspective on World ADC San Diego 2018

We caught up with two of the speakers presenting at this year's World ADC and asked, "What are you looking forward to at this...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Amid Significant Progress, Robust Growth and Advancing Pipeline — Immunogen Closes...

A leader in the expanding field of antibody-drug conjugates or ADCs for the treatment of cancer, Immunogen last week highlighted some of the company's...

Jazz Pharmaceuticals and ImmunoGen Sign Development and Commercialization Agreement

Jazz Pharmaceuticals, an international biopharmaceutical company focusing on address unmet medical needs and ImmunoGen, a clinical-stage biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate...

Debiopharm Acquires Phase II IMGN529 from ImmunoGen

Debiopharm International, a Swiss biopharmaceutical company, has confirmed that it has acquired ImmunoGen's IMGN529, also known as Debio 1562 or naratuximab emtansine, a clinical-stage anti-CD37 antibody-drug...

AACR 2017: Nine Presentations Feature ImmunoGen’s Approch to ADC development

Earlier today, ImmunoGen, a company at the forefront of antibody-drug conjugates (ADC-) development for the treatment of cancer, announced that nine abstracts highlighting the...

Data Highlights the Potential to Combine Mirvetuximab Soravtansine with an Immune...

Preclinical data demonstrate the potential for enhancing the activity of mirvetuximab soravtansine, also known as IMGN853, when the investigational agent is combined with and...

IMGN779 Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML...

CD33 is broadly expressed on leukemic blasts of patients with acute myeloid leukemia.  Although nearly 80% of patients show a high initial response rates to chemotherapy, many...

Ado-trastuzumab Emtansine Fails Phase II/III GATSBY trial

Earlier today, in a short statement to the U.S. Securities Exchange Commission (SEC), ImmunoGen, Inc. disclosed that the Phase II/III Gatsby trial, a clinical...

FEATURED RESOURCES